{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:07:01Z","timestamp":1788520021725,"version":"build-2803163510"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003121","name":"Ferdowsi University of Mashhad","doi-asserted-by":"publisher","award":["52672"],"award-info":[{"award-number":["52672"]}],"id":[{"id":"10.13039\/501100003121","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.talanta.2023.125539","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T01:58:47Z","timestamp":1702259927000},"page":"125539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Targeted delivery of elesclomol using a magnetic mesoporous platform improves prostate cancer treatment both in vitro and in vivo"],"prefix":"10.1016","volume":"270","author":[{"given":"Mojtaba","family":"Tarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Babaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Eshghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam M.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Sh","family":"Saljooghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.talanta.2023.125539_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112461","article-title":"Synthesis and biological evaluation of diaryl urea derivatives designed as potential anticarcinoma agents using de novo structure-based lead optimization approach","volume":"201","author":"Azimian","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.talanta.2023.125539_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejmech.2015.10.045","article-title":"Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents","volume":"107","author":"Chen","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.talanta.2023.125539_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11051-015-2878-8","article-title":"Comparative evaluation of polymersome versus micelle structures as vehicles for the controlled release of drugs","volume":"17","author":"Alibolandi","year":"2015","journal-title":"J. Nanoparticle Res."},{"issue":"37","key":"10.1016\/j.talanta.2023.125539_bib4","doi-asserted-by":"crossref","first-page":"15871","DOI":"10.1039\/C9NJ06445A","article-title":"Design and synthesis of aptamer AS1411-conjugated EG@ TiO 2@ Fe 2 O 3 nanoparticles as a drug delivery platform for tumor-targeted therapy","volume":"44","author":"Mansouri","year":"2020","journal-title":"New J. Chem."},{"issue":"1\u20132","key":"10.1016\/j.talanta.2023.125539_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijpharm.2016.01.040","article-title":"Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: in vitro and in vivo evaluation","volume":"500","author":"Alibolandi","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.talanta.2023.125539_bib6","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/jcp.29019","article-title":"Hybrid nanoreservoirs based on dextran\u2010capped dendritic mesoporous silica nanoparticles for CD133\u2010targeted drug delivery","volume":"235","author":"Zahiri","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"11","key":"10.1016\/j.talanta.2023.125539_bib7","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1021\/mp500389v","article-title":"Targeted delivery of doxorubicin by folic acid-decorated dual functional nanocarrier","volume":"11","author":"Lu","year":"2014","journal-title":"Mol. Pharm."},{"issue":"1\u20132","key":"10.1016\/j.talanta.2023.125539_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0378-5173(03)00380-6","article-title":"Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery","volume":"266","author":"Sameti","year":"2003","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.talanta.2023.125539_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.micromeso.2004.06.030","article-title":"Ordered mesoporous materials in catalysis","volume":"77","author":"Taguchi","year":"2005","journal-title":"Microporous Mesoporous Mater."},{"key":"10.1016\/j.talanta.2023.125539_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2021.213949","article-title":"Application of smart nanoparticles as a potential platform for effective colorectal cancer therapy","volume":"442","author":"Iranpour","year":"2021","journal-title":"Coord. Chem. Rev."},{"issue":"10","key":"10.1016\/j.talanta.2023.125539_bib11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1021\/ar200018x","article-title":"Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine","volume":"44","author":"Ambrogio","year":"2011","journal-title":"Accounts Chem. Res."},{"issue":"9","key":"10.1016\/j.talanta.2023.125539_bib12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1517\/17425247.2014.924501","article-title":"Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges","volume":"11","author":"Laurent","year":"2014","journal-title":"Expet Opin. Drug Deliv."},{"issue":"1\u20132","key":"10.1016\/j.talanta.2023.125539_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2010.05.006","article-title":"Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy","volume":"63","author":"Mahmoudi","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"43","key":"10.1016\/j.talanta.2023.125539_bib14","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1039\/C5NR04867B","article-title":"Anti-HER2\/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells","volume":"7","author":"Mu","year":"2015","journal-title":"Nanoscale"},{"issue":"1","key":"10.1016\/j.talanta.2023.125539_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1535-7163.MCT-05-0325","article-title":"Targeted delivery of methotrexate to epidermal growth factor receptor\u2013positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates","volume":"5","author":"Wu","year":"2006","journal-title":"Mol. Cancer Therapeut."},{"issue":"12","key":"10.1016\/j.talanta.2023.125539_bib16","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1016\/j.biomaterials.2014.01.019","article-title":"Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas","volume":"35","author":"Li","year":"2014","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.talanta.2023.125539_bib17","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/hep.26168","article-title":"Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma","volume":"57","author":"Yamashita","year":"2013","journal-title":"Hepatology"},{"issue":"42","key":"10.1016\/j.talanta.2023.125539_bib18","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1021\/ja5079464","article-title":"Synthetic aptamer-polymer hybrid constructs for programmed drug delivery into specific target cells","volume":"136","author":"Oh","year":"2014","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.talanta.2023.125539_bib19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2009.10.026","article-title":"EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma","volume":"52","author":"Terris","year":"2010","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.talanta.2023.125539_bib20","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2217\/nnm-2017-0028","article-title":"Synthesis of theranostic epithelial cell adhesion molecule targeted mesoporous silica nanoparticle with gold gatekeeper for hepatocellular carcinoma","volume":"12","author":"Babaei","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.talanta.2023.125539_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.1095837","article-title":"Using magnetic mesoporous silica nanoparticles armed with EpCAM aptamer as an efficient platform for specific delivery of 5-fluorouracil to colorectal cancer cells","volume":"10","author":"Kamil Mohammad Al-Mosawi","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"6","key":"10.1016\/j.talanta.2023.125539_bib22","doi-asserted-by":"crossref","first-page":"10564","DOI":"10.1002\/jcb.28342","article-title":"The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol","volume":"120","author":"Albayrak","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"8","key":"10.1016\/j.talanta.2023.125539_bib23","doi-asserted-by":"crossref","first-page":"17394","DOI":"10.3390\/ijms160817394","article-title":"Treatment strategies that enhance the efficacy and selectivity of mitochondria-targeted anticancer agents","volume":"16","author":"Modica-Napolitano","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.talanta.2023.125539_bib24","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.2741\/2446","article-title":"Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer","volume":"12","author":"Shankar","year":"2007","journal-title":"Front. Biosci."},{"issue":"5","key":"10.1016\/j.talanta.2023.125539_bib25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.dnarep.2012.02.003","article-title":"Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol","volume":"11","author":"Alli","year":"2012","journal-title":"DNA Repair"},{"issue":"1","key":"10.1016\/j.talanta.2023.125539_bib26","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41467-020-16244-2","article-title":"Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma","volume":"11","author":"Marchetto","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.talanta.2023.125539_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112175","article-title":"Repurposed drug candidates for antituberculosis therapy","author":"An","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.talanta.2023.125539_bib28","first-page":"1","article-title":"Repurposing elesclomol, an investigational drug for the treatment of copper metabolism disorders","author":"Gohil","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"5","key":"10.1016\/j.talanta.2023.125539_bib29","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s12274-018-2231-5","article-title":"Cubosome nanoparticles for enhanced delivery of mitochondria anticancer drug elesclomol and therapeutic monitoring via sub-cellular NAD(P)H multi-photon fluorescence lifetime imaging","volume":"12","author":"Faria","year":"2019","journal-title":"Nano Res."},{"issue":"1","key":"10.1016\/j.talanta.2023.125539_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-01056-3","article-title":"Improving anti-cancer drug delivery performance of magnetic mesoporous silica nanocarriers for more efficient colorectal cancer therapy","volume":"19","author":"Iranpour","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"27","key":"10.1016\/j.talanta.2023.125539_bib31","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1016\/j.biomaterials.2009.05.038","article-title":"A magnetic, luminescent and mesoporous core\u2013shell structured composite material as drug carrier","volume":"30","author":"Yang","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.talanta.2023.125539_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jcis.2014.12.053","article-title":"Fabrication of high specificity hollow mesoporous silica nanoparticles assisted by Eudragit for targeted drug delivery","volume":"445","author":"She","year":"2015","journal-title":"J. Colloid Interface Sci."},{"issue":"3","key":"10.1016\/j.talanta.2023.125539_bib33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00044-020-02673-7","article-title":"Facile one-pot sequential synthesis of novel diaryl urea derivatives and evaluation of their in vitro cytotoxicity on adenocarcinoma cells","volume":"30","author":"Azimian","year":"2021","journal-title":"Med. Chem. Res."},{"issue":"1","key":"10.1016\/j.talanta.2023.125539_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40709-021-00141-w","article-title":"Investigating the effects of two novel 4-MMPB analogs as potent lipoxygenase inhibitors for prostate cancer treatment","volume":"28","author":"Iranpour","year":"2021","journal-title":"J. Biol. Res.-Thessaloniki"},{"key":"10.1016\/j.talanta.2023.125539_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120272","article-title":"8-Geranyloxycarbostyril as a potent 15-LOX-1 inhibitor showed great anti-tumor effects against prostate cancer","volume":"293","author":"Aghasizadeh","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.talanta.2023.125539_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111618","article-title":"Ladder-like targeted and gated doxorubicin delivery using bivalent aptamer in vitro and in vivo","volume":"119","author":"Charbgoo","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"issue":"1\u20132","key":"10.1016\/j.talanta.2023.125539_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/03086648808079002","article-title":"Organische phosphorverbindungen 841. HERSTELLUNG, eigenschaften und biologische wirkung VON hydrazinomethyl-phosphon- und -phosphins\u00e4uren und derivaten","volume":"36","author":"Diel","year":"1988","journal-title":"Phosphorus Sulfur Relat. Elem."},{"issue":"27","key":"10.1016\/j.talanta.2023.125539_bib38","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1021\/jm049556d","article-title":"Synthesis and antitumor activity of methyltriazene prodrugs simultaneously releasing DNA-methylating agents and the antiresistance drug O 6-benzylguanine","volume":"47","author":"Wanner","year":"2004","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.talanta.2023.125539_bib39","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1016\/j.bmcl.2013.07.032","article-title":"Syntheses and antitumor activities of N\u20321,N\u20323-dialkyl-N\u20321,N\u20323-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol","volume":"23","author":"Chen","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"2","key":"10.1016\/j.talanta.2023.125539_bib40","first-page":"76","article-title":"The role of gold nanoparticles\/Au-PEG-PAMAM as drug delivery system for treatment of breast cancer","volume":"2","author":"Murtadha","year":"2023","journal-title":"Biomed. Chem. Sci."},{"key":"10.1016\/j.talanta.2023.125539_bib41","article-title":"Drug-loaded PEG-PLGA nanoparticles for cancer treatment","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.talanta.2023.125539_bib42","article-title":"Preparation and evaluation of PLGA-PEG\/Gusperimus nanoparticles as a controlled delivery anti-inflammatory drug","volume":"77","author":"Palacio","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.talanta.2023.125539_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120287","article-title":"Preparation and evaluation of PEG-coated zein nanoparticles for oral drug delivery purposes","volume":"597","author":"Reboredo","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.talanta.2023.125539_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.polymer.2020.122901","article-title":"Biodegradable diblock copolymeric PEG-PCL nanoparticles: synthesis, characterization and applications as anticancer drug delivery agents","volume":"207","author":"Behl","year":"2020","journal-title":"Polymer"},{"issue":"10","key":"10.1016\/j.talanta.2023.125539_bib45","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1039\/C8BM00625C","article-title":"FA-PEG decorated MOF nanoparticles as a targeted drug delivery system for controlled release of an autophagy inhibitor","volume":"6","author":"Shi","year":"2018","journal-title":"Biomater. Sci."},{"issue":"8","key":"10.1016\/j.talanta.2023.125539_bib46","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-08-0298","article-title":"Elesclomol induces cancer cell apoptosis through oxidative stress","volume":"7","author":"Kirshner","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"issue":"4","key":"10.1016\/j.talanta.2023.125539_bib47","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1021\/acsami.9b20603","article-title":"Combined magnetoliposome formation and drug loading in one step for efficient alternating current-magnetic field remote-controlled drug release","volume":"12","author":"Fortes Brollo","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"10","key":"10.1016\/j.talanta.2023.125539_bib48","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/pharmaceutics12100957","article-title":"Mesoporous silica nanoparticles as theranostic antitumoral nanomedicines","volume":"12","author":"Baeza","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.talanta.2023.125539_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2019.02.031","article-title":"Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer","volume":"89","author":"Li","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.talanta.2023.125539_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-02031-4","article-title":"Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth","volume":"40","author":"Buccarelli","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.talanta.2023.125539_bib51","doi-asserted-by":"crossref","first-page":"2212267","DOI":"10.1002\/adma.202212267","article-title":"Cuproptosis induced by ROS responsive nanoparticles with elesclomol and copper combined with \u03b1PD\u2010L1 for enhanced cancer immunotherapy","volume":"35","author":"Guo","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.talanta.2023.125539_bib52","first-page":"54","article-title":"Targeted apoptosis of myofibroblasts by elesclomol inhibits hypertrophic scar formation","author":"Feng","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.talanta.2023.125539_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-022-02485-0","article-title":"Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy","volume":"41","author":"Zheng","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"27","key":"10.1016\/j.talanta.2023.125539_bib54","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1038\/s41388-022-02364-0","article-title":"Copper ionophore elesclomol selectively targets GNAQ\/11-mutant uveal melanoma","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.talanta.2023.125539_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2216722120","article-title":"FDX1-dependent and independent mechanisms of elesclomol-mediated intracellular copper delivery","volume":"120","author":"Zulkifli","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.talanta.2023.125539_bib56","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1002\/1878-0261.13079","article-title":"Elesclomol induces copper\u2010dependent ferroptosis in colorectal cancer cells via degradation of ATP7A","volume":"15","author":"Gao","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.talanta.2023.125539_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinorgbio.2013.04.013","article-title":"Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu (II), Ni (II) and Pt (II)","volume":"126","author":"Yadav","year":"2013","journal-title":"J. Inorg. Biochem."},{"issue":"5","key":"10.1016\/j.talanta.2023.125539_bib58","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s12274-018-2231-5","article-title":"Cubosome nanoparticles for enhanced delivery of mitochondria anticancer drug elesclomol and therapeutic monitoring via sub-cellular NAD (P) H multi-photon fluorescence lifetime imaging","volume":"12","author":"Faria","year":"2019","journal-title":"Nano Res."},{"key":"10.1016\/j.talanta.2023.125539_bib59","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.msec.2016.08.054","article-title":"Synthesis and characterization of mesoporous magnetic nanocomposites wrapped with chitosan gatekeepers for pH-sensitive controlled release of doxorubicin","volume":"70","author":"Wu","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"issue":"10","key":"10.1016\/j.talanta.2023.125539_bib60","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.bbagen.2016.07.001","article-title":"Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells","volume":"1860","author":"Sarkar","year":"2016","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.talanta.2023.125539_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118645","article-title":"Hybrid silica-coated Gd-Zn-Cu-In-S\/ZnS bimodal quantum dots as an epithelial cell adhesion molecule targeted drug delivery and imaging system","volume":"570","author":"Akbarzadeh","year":"2019","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.talanta.2023.125539_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2007.08.001","article-title":"Nanoparticles for drug delivery: the need for precision in reporting particle size parameters","volume":"69","author":"Gaumet","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.talanta.2023.125539_bib63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jinorgbio.2014.04.004","article-title":"The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu (II)","volume":"137","author":"Hasinoff","year":"2014","journal-title":"J. Inorg. Biochem."},{"issue":"8","key":"10.1016\/j.talanta.2023.125539_bib64","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/biom9080298","article-title":"The anticancer agent elesclomol has direct effects on mitochondrial bioenergetic function in isolated mammalian mitochondria","volume":"9","author":"Modica-Napolitano","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.talanta.2023.125539_bib65","series-title":"Elesclomol Sodium and Paclitaxel in Treating Patients with Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","author":"gov","year":"2009"},{"key":"10.1016\/j.talanta.2023.125539_bib66","series-title":"Study Elesclomol Sodium in Patients with Relapsed or Refractory Acute Myeloid Leukemia","author":"gov","year":"2011"},{"key":"10.1016\/j.talanta.2023.125539_bib67","series-title":"A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given with a Fixed Dose of Docetaxel and Prednisone in Patients with Metastatic Prostate Cancer","author":"gov","year":"2008"},{"issue":"9","key":"10.1016\/j.talanta.2023.125539_bib68","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/10837450.2019.1569678","article-title":"Pegylated magnetic mesoporous silica nanoparticles decorated with AS1411 Aptamer as a targeting delivery system for cytotoxic agents","volume":"24","author":"Sakhtianchi","year":"2019","journal-title":"Pharmaceut. Dev. Technol."},{"issue":"8","key":"10.1016\/j.talanta.2023.125539_bib69","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.nano.2017.08.006","article-title":"MUC1 aptamer-capped mesoporous silica nanoparticles for controlled drug delivery and radio-imaging applications","volume":"13","author":"Pascual","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.talanta.2023.125539_bib70","doi-asserted-by":"crossref","first-page":"118111","DOI":"10.1016\/j.carbpol.2021.118111","article-title":"Targeted delivery system using silica nanoparticles coated with chitosan and AS1411 for combination therapy of doxorubicin and antimiR-21","volume":"266","author":"Khatami","year":"2021","journal-title":"Carbohydr. Polym."},{"issue":"11","key":"10.1016\/j.talanta.2023.125539_bib71","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1021\/acs.molpharmaceut.9b00867","article-title":"EpCAM aptamer-functionalized cationic liposome-based nanoparticles loaded with miR-139-5p for targeted therapy in colorectal cancer","volume":"16","author":"Zhao","year":"2019","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.talanta.2023.125539_bib72","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijpharm.2014.12.035","article-title":"Epithelial cell adhesion molecule aptamer conjugated PEG\u2013PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro","volume":"479","author":"Alibolandi","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.talanta.2023.125539_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132407","article-title":"EpCAM aptamer-siRNA chimera targets and regress epithelial cancer","volume":"10","author":"Subramanian","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.talanta.2023.125539_bib74","first-page":"2022","article-title":"The molecular mechanisms of defective copper metabolism in diabetic cardiomyopathy","author":"Cui","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.talanta.2023.125539_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105207","article-title":"Na+\/K+ ATPase-targeted delivery to metastatic breast cancer models","volume":"143","author":"Araste","year":"2020","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.talanta.2023.125539_bib76","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejpb.2016.12.009","article-title":"In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy","volume":"113","author":"Mosafer","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.talanta.2023.125539_bib77","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7150\/thno.17259","article-title":"Enhanced blood suspensibility and laser-activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes","volume":"7","author":"Su","year":"2017","journal-title":"Theranostics"},{"issue":"19","key":"10.1016\/j.talanta.2023.125539_bib78","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1002\/chem.201203003","article-title":"A Top\u2010Down synthesis route to ultrasmall multifunctional Gd\u2010Based silica nanoparticles for theranostic applications","volume":"19","author":"Mignot","year":"2013","journal-title":"Chem.--Eur. J."},{"issue":"11","key":"10.1016\/j.talanta.2023.125539_bib79","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1039\/C5TB02490K","article-title":"MMP-responsive theranostic nanoplatform based on mesoporous silica nanoparticles for tumor imaging and targeted drug delivery","volume":"4","author":"Hu","year":"2016","journal-title":"J. Mater. Chem. B"},{"issue":"11","key":"10.1016\/j.talanta.2023.125539_bib80","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/adma.201104714","article-title":"Mesoporous silica\u2010coated gold nanorods as a light\u2010mediated multifunctional theranostic platform for cancer treatment","volume":"24","author":"Zhang","year":"2012","journal-title":"Adv. Mater."},{"issue":"19","key":"10.1016\/j.talanta.2023.125539_bib81","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1002\/adfm.201303533","article-title":"Cancer\u2010targeted monodisperse mesoporous silica nanoparticles as carrier of ruthenium polypyridyl complexes to enhance theranostic effects","volume":"24","author":"He","year":"2014","journal-title":"Adv. Funct. Mater."}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914023012900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914023012900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T13:16:49Z","timestamp":1758547009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039914023012900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":81,"alternative-id":["S0039914023012900"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2023.125539","relation":{},"ISSN":["0039-9140"],"issn-type":[{"value":"0039-9140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted delivery of elesclomol using a magnetic mesoporous platform improves prostate cancer treatment both in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2023.125539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"125539"}}